temozolomide + anlotinib + pembrolizumab

This is a **combination regimen** consisting of temozolomide, anlotinib, and pembrolizumab—three pharmaceutical agents with distinct mechanisms. - **Temozolomide** is an oral alkylating agent that exerts cytotoxic effects by methylating DNA, leading to apoptosis in cancer cells. - **Anlotinib** is an oral small molecule multitargeted tyrosine kinase inhibitor that blocks angiogenesis and tumor proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. - **Pembrolizumab** is a humanized monoclonal antibody that inhibits PD-1, a checkpoint receptor on T cells, enhancing anti-tumor immunity. This triplet regimen is under clinical investigation for recurrent glioblastoma and potentially other advanced solid tumors, aiming to combine cytotoxic, antiangiogenic, and immunotherapeutic effects for synergistic anti-tumor activity[1][3][5][9].